Diphenhydramine — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

3 Recruiting

7 Completed trials

10 Sponsors

14 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase I

Phase I (FiH)

Phase III: 3 Phase II/III: 1 Phase II: 2 Phase I/II: 2 Phase I: 1 Phase I (FiH): 1

Oversight events:

10 temporary halts 1 corrective measure across 2 trials

View oversight register →

Indications tested

Relapsing multiple sclerosis 2 Metastatic malignant melanoma 1 Uveal melanoma 1 Myasthenia gravis 1

Sponsors using this IMP

Tg Therapeutics Inc. 2 AbbVie Deutschland GmbH & Co. KG 1 AstraZeneca AB 1 BioInvent International AB 1 Emn Trial Office S.r.l. Impresa Sociale 1 European Myeloma Network B.V. 1 F. Hoffmann-La Roche AG 1 Fondazione Gimema Franco Mandelli Onlus 1 Immunocore Limited 1 Kite Pharma Inc. 1

All trials

10 total

Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Phase III 1 country Tg Therapeutics Inc.
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting

2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting

2022-502732-39-00 Phase II/III 7 countries Immunocore Limited
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Ended

2022-501489-24-00 Phase III 7 countries Kite Pharma Inc.
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Phase I 1 country Tg Therapeutics Inc.
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended

2023-503689-21-00 Phase I/II 5 countries F. Hoffmann-La Roche AG
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to… Ended

2022-503066-74-00 Phase I (FiH) 5 countries Bioinvent International AB
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Ended

2022-502773-41-00 Phase I/II 4 countries AstraZeneca AB

Showing 1–10 of 10 trials

← All drugs A–Z